Oct122017 Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET October 12, 2017
Sep52017 Anavex®Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 September 5, 2017
Jul202017 Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board July 20, 2017
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference May 22, 2017
May222017 Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference − May 22, 2017
